H-吴越投资2020-03-04 21:57
春节期间对血液灌流治疗进行初步研究,对采用全血灌流和血浆灌流的产品做了一些疏理,附以我个人的一些理解。相关公司列表如下:
表一、血浆吸附:
注:
(1)血浆吸附模式提前将血液中的血细胞分离出来,吸附效率更佳,还可以避免或减少血液相容性问题。血液相容性可能是因为离子树脂...查看全文
$Cytosorbents(CTSO)$ 8-K Current report, items 2.02, 8.01, and 9.01 Accession Number: 0001104659-23-008819 Act: 34 Size: 345 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 1.01, 8.01, and 9.01 Accession Number: 0001104659-22-130966 Act: 34 Size: 266 KB 网页链接
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-125893 Size: 6 KB 网页链接
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-125503 Size: 7 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-22-119569 Act: 34 Size: 240 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-22-114483 Act: 34 Size: 537 KB 网页链接
$Cytosorbents(CTSO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001410578-22-002932 Act: 34 Size: 7 MB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001104659-22-106813 Act: 34 Size: 247 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-22-103441 Act: 34 Size: 235 KB 网页链接
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-22-099104 Size: 6 KB 网页链接